Cellectar Biosc (CLRB)

$0.38 -0.03 (-7.50%)
Market Cap 19.04M
Revenue (ttm) 0.00
Net Income (ttm) -44.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,896,800
Avg Vol 14,842,384
Day's Range N/A - N/A
Shares Out 46.08M
Stochastic %K 17%
Beta 0.52
Analysts Sell
Price Target $4.00

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology
Sector: Healthcare
Phone: 608 441 8120
Address:
100 Campus Drive, Florham Park, United States
stevenryl86
stevenryl86 Jun. 17 at 6:50 AM
$CLRB so quiet? No update on offering close? Silence is good? Buyout imminent?
0 · Reply
CrazyStockup
CrazyStockup Jun. 16 at 11:30 PM
$CLRB
0 · Reply
CrazyStockup
CrazyStockup Jun. 16 at 11:29 PM
$CLRB
0 · Reply
cyclohexane
cyclohexane Jun. 16 at 9:16 PM
$CLRB https://www.stockinsights.ai/us/CLRB/8-K/capital-structure-changes-20250613-063?utm_source=twitter&utm_medium=social&utm_id=secfilingsdigest "The Company requested approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The stockholders approved the compensation of the named executive officers." Company barely surviving on any money. Barely get through Phase 4 at this point. Make sure to kill any stock momentum by dilution but you also approve a RS and make sure Caruso gets paid.
0 · Reply
ClipSave
ClipSave Jun. 16 at 9:11 PM
$CLRB Why does this POS always fall hard AH?
0 · Reply
transamlover
transamlover Jun. 16 at 9:02 PM
$CLRB
0 · Reply
Jay88888888
Jay88888888 Jun. 16 at 9:01 PM
$CLRB .. slow bleed.not liking this at all and now some knucklehead is talking RS.. this is bullshit
0 · Reply
MicsMugz
MicsMugz Jun. 16 at 8:07 PM
$CLRB $CYTO Looking good today in my hand of cards thou. $HOVR Load up the Truck.
0 · Reply
MicsMugz
MicsMugz Jun. 16 at 7:59 PM
$CLRB Actually right now i would look around for a small-cap aero area for flying hov,s.Trump just announced the plan to accelerate it, and you know who else will get loaded more than he is, you guess? Ill post a couple goods one to load up on.
0 · Reply
MicsMugz
MicsMugz Jun. 16 at 7:55 PM
$CLRB Steady as she goes Bro,s,and Yo,s. Not a great day not a bad day right at my average. The big hedges are on this as well i seee wITH the vangaurds loaded up Black Rockers,The big mofo,s
0 · Reply
Latest News on CLRB
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Jun 11, 2025, 8:05 AM EDT - 5 days ago

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Jun 5, 2025, 9:00 AM EDT - 11 days ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Jun 4, 2025, 8:05 AM EDT - 12 days ago

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript

May 13, 2025, 2:17 PM EDT - 4 weeks ago

Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025, 7:05 AM EDT - 4 weeks ago

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

May 7, 2025, 8:05 AM EDT - 5 weeks ago

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

Cellectar Announces Plan to Explore Strategic Alternatives

Apr 30, 2025, 8:05 AM EDT - 6 weeks ago

Cellectar Announces Plan to Explore Strategic Alternatives

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 12:41 PM EDT - 3 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Mar 13, 2025, 7:05 AM EDT - 3 months ago

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Mar 5, 2025, 8:05 AM EST - 3 months ago

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:05 AM EST - 4 months ago

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Jan 12, 2025, 6:00 PM EST - 5 months ago

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Dec 11, 2024, 11:25 AM EST - 6 months ago

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Dec 10, 2024, 5:00 PM EST - 6 months ago

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Nov 21, 2024, 8:00 AM EST - 7 months ago

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 10:59 AM EST - 7 months ago

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Nov 18, 2024, 7:05 AM EST - 7 months ago

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Nov 14, 2024, 8:05 AM EST - 7 months ago

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Nov 12, 2024, 8:05 AM EST - 7 months ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Nov 11, 2024, 4:05 PM EST - 7 months ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Nov 7, 2024, 6:40 AM EST - 7 months ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Nov 1, 2024, 5:00 PM EDT - 8 months ago

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Aug 26, 2024, 6:40 AM EDT - 10 months ago

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Aug 23, 2024, 5:00 PM EDT - 10 months ago

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 1:25 PM EDT - 10 months ago

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Aug 13, 2024, 6:40 AM EDT - 10 months ago

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Aug 8, 2024, 5:15 PM EDT - 11 months ago

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript

Jul 24, 2024, 3:22 PM EDT - 11 months ago

Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript

Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones

Jul 23, 2024, 3:09 PM EDT - 11 months ago

Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

Jul 23, 2024, 10:49 AM EDT - 11 months ago

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Jul 23, 2024, 6:40 AM EDT - 11 months ago

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

Jul 22, 2024, 6:40 AM EDT - 11 months ago

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

Jun 27, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

May 29, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

May 20, 2024, 1:02 PM EDT - 1 year ago

Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript

May 14, 2024, 1:05 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

May 14, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

May 8, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024

May 7, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 12:27 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Mar 27, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

Mar 20, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

Cellectar Biosciences to Present at the 36th Annual Roth Conference

Mar 14, 2024, 8:52 AM EDT - 1 year ago

Cellectar Biosciences to Present at the 36th Annual Roth Conference

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Mar 4, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Feb 12, 2024, 1:34 AM EST - 1 year ago

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

Jan 30, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

Jan 25, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient

Jan 22, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patient

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data

Jan 16, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data

stevenryl86
stevenryl86 Jun. 17 at 6:50 AM
$CLRB so quiet? No update on offering close? Silence is good? Buyout imminent?
0 · Reply
CrazyStockup
CrazyStockup Jun. 16 at 11:30 PM
$CLRB
0 · Reply
CrazyStockup
CrazyStockup Jun. 16 at 11:29 PM
$CLRB
0 · Reply
cyclohexane
cyclohexane Jun. 16 at 9:16 PM
$CLRB https://www.stockinsights.ai/us/CLRB/8-K/capital-structure-changes-20250613-063?utm_source=twitter&utm_medium=social&utm_id=secfilingsdigest "The Company requested approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The stockholders approved the compensation of the named executive officers." Company barely surviving on any money. Barely get through Phase 4 at this point. Make sure to kill any stock momentum by dilution but you also approve a RS and make sure Caruso gets paid.
0 · Reply
ClipSave
ClipSave Jun. 16 at 9:11 PM
$CLRB Why does this POS always fall hard AH?
0 · Reply
transamlover
transamlover Jun. 16 at 9:02 PM
$CLRB
0 · Reply
Jay88888888
Jay88888888 Jun. 16 at 9:01 PM
$CLRB .. slow bleed.not liking this at all and now some knucklehead is talking RS.. this is bullshit
0 · Reply
MicsMugz
MicsMugz Jun. 16 at 8:07 PM
$CLRB $CYTO Looking good today in my hand of cards thou. $HOVR Load up the Truck.
0 · Reply
MicsMugz
MicsMugz Jun. 16 at 7:59 PM
$CLRB Actually right now i would look around for a small-cap aero area for flying hov,s.Trump just announced the plan to accelerate it, and you know who else will get loaded more than he is, you guess? Ill post a couple goods one to load up on.
0 · Reply
MicsMugz
MicsMugz Jun. 16 at 7:55 PM
$CLRB Steady as she goes Bro,s,and Yo,s. Not a great day not a bad day right at my average. The big hedges are on this as well i seee wITH the vangaurds loaded up Black Rockers,The big mofo,s
0 · Reply
Slab6
Slab6 Jun. 16 at 6:52 PM
$CLRB RS news and only down 5%? Not bad at all
1 · Reply
transamlover
transamlover Jun. 16 at 5:58 PM
$CLRB ....bought some November 50 cent calls, see what happens here....
0 · Reply
CookamungaCrackerKillaz
CookamungaCrackerKillaz Jun. 16 at 12:48 PM
$CLRB come Pick me up at .54 folks on the way to $1.00
1 · Reply
sgar9591
sgar9591 Jun. 16 at 12:39 PM
$CLRB In a just society Caruso and his BOD would be in jail for fraud. This company has been doing the same shite for over 20 years with absolutely nothing to show for it.
2 · Reply
MicsMugz
MicsMugz Jun. 16 at 12:37 PM
$CLRB .46 lets bust it.
0 · Reply
MicsMugz
MicsMugz Jun. 16 at 12:36 PM
$CLRB t minus .40
0 · Reply
Kilihg
Kilihg Jun. 16 at 12:28 PM
$CLRB
0 · Reply
MotheRussia
MotheRussia Jun. 16 at 12:09 PM
$CLRB
0 · Reply
Fonzinatrix
Fonzinatrix Jun. 16 at 10:53 AM
$CLRB let the buy out offers roll in!
1 · Reply
MicsMugz
MicsMugz Jun. 16 at 5:55 AM
$CLRB They will be bought out or jv I cant see this sitting long.
1 · Reply
stevenryl86
stevenryl86 Jun. 16 at 1:51 AM
$CLRB any further drop, I will by some. They need good news! Buyout!
2 · Reply
MicsMugz
MicsMugz Jun. 16 at 1:36 AM
$CLRB Page 3 info
0 · Reply